Abbreviations and Acronyms

        4D
        Die Deutsche Diabetes Dialyse Studie
        ACCORD
        Action to Control Cardiovascular Risk in Diabetes trial
        AGREE
        Appraisal of Guidelines for Research and Evaluation
        ALERT
        Assessment of Lescol in Renal Transplantation trial
        ALLHAT
        Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial
        ALLIANCE
        Aggressive Lipid Lowering Initiation Abates New Cardiac Events trial
        ApoB
        Apolipoprotein B
        ASPEN
        Atorvastatin as Prevention of Coronary Heart Disease Endpoints in Patients with Non-Insulin-Dependent Diabetes Mellitus trial
        ASSIGN
        ASSessing cardiovascular risk using SIGN guidelines
        ATP
        Adult Treatment Panel
        AURORA
        A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events
        CARDS
        Collaborative Atorvastatin Diabetes Study
        CARE
        Cholesterol and Recurrent Events trial
        CHD
        Coronary heart disease
        CI
        Confidence interval
        CK
        Creatine kinase
        CKD
        Chronic kidney disease
        CKiD
        Chronic Kidney Disease in Children study
        COGS
        Conference on Guideline Standardization
        CPG
        Clinical practice guideline
        CVD
        Cardiovascular disease
        DAIS
        Diabetes Atherosclerosis Intervention Study
        eGFR
        Estimated glomerular filtration rate
        ERT
        Evidence review team
        ESRD
        End-stage renal disease
        FIELD
        Fenofibrate Intervention and Event Lowering in Diabetes trial
        GFR
        Glomerular filtration rate
        GRADE
        Grading of Recommendations Assessment, Development, and Evaluation
        HD
        Hemodialysis
        HDL-C
        High-density lipoprotein cholesterol
        HR
        Hazard ratio
        IDEAL
        Incremental Decrease in Endpoints Through Aggressive Lipid Lowering trial
        KDIGO
        Kidney Disease: Improving Global Outcomes
        KDOQI
        Kidney Disease Outcomes Quality Initiative
        LDL-C
        Low-density lipoprotein cholesterol
        Lp(a)
        Lipoprotein(a)
        MI
        Myocardial infarction
        NKF
        National Kidney Foundation
        PDAY
        Pathobiological Determinants of Atherosclerosis in Youth study
        PICODD
        Population, Intervention, Comparator, Outcome, study Design and Duration of follow-up
        PREVEND
        IT Prevention of REnal and Vascular ENdstage Disease Intervention Trial
        PROCAM
        Prospective Cardiovascular Münster
        PROSPER
        Prospective Study of Pravastatin in the Elderly at Risk trial
        PROVE IT
        Pravastatin or Atorvastatin in Evaluation and Infection Therapy trial
        QRISK2
        QRISK cardiovascular disease risk algorithm version 2
        RCT
        Randomized controlled trial
        RR
        Relative risk
        SCORE
        Systematic Coronary Risk Evaluation Project
        SCr
        Serum creatinine
        SEARCH
        Study Evaluating Additional Reductions in Cholesterol and Homocysteine
        SHARP
        Study of Heart and Renal Protection trial
        SPARCL
        Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial
        TC
        Total cholesterol
        TG
        Triglyceride
        TLC
        Therapeutic lifestyle changes
        TNT
        Treating to New Targets trial
        VA-HIT
        Veterans’ Affairs high-density lipoprotein intervention trial